Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis

Documenti analoghi

• Sacituzumab tirumotecan improved survival for patients with EGFR TKI–resistant, EGFR‐mutant advanced NSCLC
  di: Leah Lawrence
  Pubblicazione: (2026)
• Magnoliae flos Overcomes EGFR ‐ TKI Resistance in NSCLC by Enhancing EGFR Ubiquitination
  di: Qing Wu, et al.
  Pubblicazione: (2026)
• Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
  di: Wei‐Chun Chen, et al.
  Pubblicazione: (2024)
• Comparative Survival Analysis of Anti‐Angiogenic Agent Plus Immunochemotherapy in NSCLC Patients After Frontline EGFR‐TKI Treatment: A Retrospective Cohort Study
  di: Yi‐Tse Su, et al.
  Pubblicazione: (2025)
• More treatment options emerge for EGFR ‐mutant NSCLC
  di: Leah Lawrence
  Pubblicazione: (2026)